The COLIA1 gene is a strong candidate for susceptibility to osteoporosis. The causal genetic variants are currently unclear, but the most likely are functional polymorphisms in the promoter and intron 1 of COLIA1.
O STEOPOROSIS IS A common disorder characterized
by low bone mass, microarchitectural deterioration of bone tissue, and enhanced bone fragility leading to an increased incidence of fracture. Genetic factors are recognized to play an important role in the regulation of bone mass and other phenotypes relevant to the pathogenesis of osteoporosis such as bone turnover, bone geometry, and fracture itself (1) . Many candidate gene polymorphisms have been implicated in the pathogenesis of osteoporosis, but one of the most widely studied is a polymorphism that affects Sp1 binding site in the first intron of the COLIA1 gene at position ϩ1245 relative to the transcription start site (rs1800012) (2) . The COLIA1 Sp1 binding site polymorphism has been associated with bone density (2, 3) , fragility fractures (2, 3) , and other osteoporosis-related phenotypes such as postmenopausal bone loss (4, 5) , bone geometry (6), bone quality (7), and bone mineralization (8) . Functional analysis has shown that the osteoporosis-associated T allele ("s") of the Sp1 polymorphism is associated with increased DNA-protein binding, increased transcription, and abnormally increased production of the collagen type I␣1 mRNA and protein (7) . It is thought that the resulting imbalance between the type I collagen ␣I and ␣2 chains contributes to impairment of bone strength and reduced bone mass in carriers of the T allele by subtly affecting bone mineralization (8) . Retrospective metaanalyses of published studies concluded that carriage of the T allele is associated with reduced bone mineral density (BMD) at the lumbar spine and femoral neck and vertebral fractures (7, 9, 10) . Moreover, homozygotes for the T allele of the Sp1 polymorphism were recently found to be associated with BMD and incident vertebral fractures in a large prospective meta-analysis of more than 20,000 participants of the Genetic Markers for Osteoporosis (GENOMOS) study, which included subjects from the population described here (11) .
We also previously reported that the association between COLIA1 alleles and vertebral fracture in women from northeast Scotland was primarily driven by the Sp1 binding site polymorphism rather than other known polymorphisms at the COLIA1 locus (12) . Since publication of this study, however, two other polymorphisms have been identified in the promoter of COLIA1, which are in strong linkage disequilibrium (LD) with the Sp1 binding site polymorphism (13) .
These are a G/T polymorphism at position Ϫ1997 relative to the transcription start site (Ϫ1997G/T; rs1107946) and an insertion/deletion polymorphism at position Ϫ1663 (Ϫ1663indelT; rs2412298). These polymorphisms were found to interact with each other and with the Sp1 polymorphism to regulate BMD in a small study of Spanish postmenopausal women (13) and to influence COLIA1 transcription in promoter-reporter assays (14) . The Ϫ1997G/T promoter polymorphism has been studied in relation to BMD in other populations and family-based studies with mixed results, although most of these studies have been of limited sample size (15) (16) (17) . In this study, therefore, we examined associations between BMD and the promoter and Sp1 binding site polymorphisms of the COLIA1 gene and haplotypes defined by these polymorphisms in a large, population-based study of 3270 predominantly postmenopausal women from the United Kingdom.
Subjects and Methods Subjects
The study subjects participated in a population-based screening study for osteoporotic fracture risk, involving 5119 unrelated women aged 45-54 yr who were recruited at random from the general population within a 32-km radius of Aberdeen by use of the Community Heath Index number as previously described (18) . Participants underwent bone densitometry between 1990 and 1994 and completed a risk factor questionnaire including questions on menopausal status and use of hormone replacement therapy (HRT) as previously described (19) . Weight was measured on a set of balanced scales calibrated to 0.05 kg (SECA, Hamburg, Germany), and height was measured with a stadiometer (Holtain, Ltd., Crymych, UK). Women were classified as premenopausal if they were menstruating regularly, perimenopausal if their menstruation was irregular and/or up to 6 months had elapsed since their last period, and postmenopausal if their menstruation had ceased for 6 months or more. After this assessment, the BMD results were disclosed to participants and their general practitioners, and subjects with BMD values in the lowest quartile of the population were advised to consider taking HRT therapy as prophylaxis against osteoporosis (18). Previous studies have shown that the uptake of HRT in participants of this study (approximately 30%) is 6% greater than in women from the same region who had not undergone BMD screening (18) .
All participants were invited to undergo further assessment between 1997 and 1999, and a total of 3883 women of the original 5119 attended (75.8%). At this time, the baseline questionnaire was repeated, and additional information was collected on smoking habit and physical activity using a questionnaire that was previously used in the Scottish Heart Health Study (20) , which gives a physical activity level (PAL) score, calculated from the number of hours in a 24-h period doing heavy, moderate, or light activities and how many hours are spent sleeping or resting in bed. Participants in the present study comprised 3270 women who consented to give blood samples for DNA extraction at the follow-up visit and were successfully genotyped for at least one of the polymorphisms studied.
Bone density measurements
BMD was measured at the femoral neck and lumbar spine (L2-4) by dual-energy x-ray absorptiometry using XR26 and XR36 densitometers (Norland, Fort Atkinson, WI). The majority of women were scanned using an XR26 machine, but 357 women (11.5%) were scanned using an XR36 machine. Cross-calibration of the machines was done using the manufacturer's phantom, and this revealed a small difference (1.258%) in mean BMD value between the machines. This correction factor was used to convert the XR36 values to XR26-equivalent values. We previously validated this approach, and the use of the scanner-corrected BMD values has been shown to give similar results to analyses in which scanner type is entered into the statistical model as a random factor in assessing genotype-specific differences in BMD (21) . There were no significant differences in the proportion of women scanned on each machine across different genotypes.
Genotyping
Genotyping for Ϫ1997G/T and Ϫ1663indelT polymorphisms was carried out by DNA sequencing of PCR-amplified fragments of genomic DNA, whereas genotyping for the COLIA1 Sp1 polymorphism was carried out predominantly by TaqMan analysis as previously described (22) . All PCRs were performed in 96-well plates in a 25-l volume containing 2.5 l 10ϫ PCR buffer (QIAGEN Ltd, Crawly, UK), 2.0 l deoxynucleotide triphosphate (10 mm each), 5.0 l Q-solution, 2.5 l of oligonucleotide primer mix (5 m each of forward and reverse primer), 0.625 U Taq DNA polymerase (QIAGEN), and approximately 50 ng genomic DNA. The PCRs were carried out on a Gene Engine thermocycler (MJ Research Inc., Waltham, MA). The PCR products were treated with ExoSAP IT (USB Corp., Cleveland, OH) according to the manufacturer's instructions and sequenced using the DYEnamic ET dye terminator cycle sequencing kit (Amersham Pharmacia Biotech U.K. Ltd., Buckinghamshire, UK) according to the manufacturer's instructions. The sequencing reactions were analyzed using a MEGABACE automated DNA sequencer (Amersham Pharmacia Biotech).
For the Ϫ1663 and Ϫ1997 polymorphisms, we generated a 513-bp fragment using the following primers: 5Ј-TCACTAACCCTCATAC-TACCAAGC-3Ј and 5Ј-AAGATTCCATTGCCTCCCCC-3Ј, and this was sequenced using these primers or an internal reverse primer 5Ј-CCTT-TAATTATAGCCCCTGCA-3Ј. The thermal cycling protocol for both fragments consisted of an initial incubation for 5 min at 94 C, followed by 31 cycles of 60 sec at 94 C, 30 sec at 61 C, and 60 sec of 72 C followed by an extension step at 72 C for 5 min in the last cycle. A random sample of approximately 5% of subjects were genotyped twice for each polymorphism to assess the genotyping error rate, and this showed 100% concordance between genotyping runs. For the Ϫ1663indelT polymorphism, all subjects who were heterozygous or homozygous for the Ϫ1663delT allele were genotyped twice, with 100% concordance between genotyping runs. Genotyping was successfully performed for the COLIA1 Sp1 polymorphism in 3225 individuals, the Ϫ1997G/T polymorphism in 3011 individuals, and the Ϫ1663indelT polymorphism in 2986 individuals. Haplotypes were estimated from genotype data for individual participants using the PHASE program (23) . For the purpose of statistical analysis, we only used haplotype data in which the probability of correct haplotype assignment by PHASE in an individual case was estimated as 95% or greater.
Statistical analysis
Statistical analyses were performed using Minitab (version 12.23; State College, PA). The 2 test was used to test for Hardy-Weinberg equilibrium. Levene's test was used to check for equality of variances between genotype and haplotype groups. Differences in BMD values between genotypes and haplotypes were analyzed by ANOVA at the baseline and follow-up visit using the general linear model routine of Minitab. For this analysis, genotypes and haplotypes were entered into the model along with other potential predictors such as body mass index (BMI), PAL score, age, smoking (current smoker or nonsmoker), menopausal status (premenopausal vs. perimenopausal and postmenopausal), and HRT use (never used HRT, previously used HRT, current use of HRT). A similar analysis was performed for BMD values at the baseline visit, but here only genotype or haplotype, age, BMI, HRT use, and menopausal status were entered into the model because information on smoking and PAL was not available at this time point. When significant differences were detected between genotype or haplotype groups using this procedure, the means were compared between groups using Tukey's test. Analysis of the BMD data using Levene's test showed no significant difference in variances for any of the individual genotype or haplotype groups studied. Multiple regression analysis and stepwise multiple regression analysis were used to evaluate associations between genotypes and haplotypes and BMD and estimate the effect size of the genotype and haplotypes in relation to other predictors of BMD. For this analysis, continuous variables (age, BMI, and PAL) were entered into the statistical model as covariates. For categorical variables, such as menopausal status, HRT use, and COLIA1 genotype and haplotype, dummy variables were constructed for use in the multiple regression analysis.
Although we performed multiple statistical tests of three polymorphisms (and haplotypes defined by these polymorphisms) in relation to BMD at baseline and follow-up at two skeletal sites, these factors were interrelated and therefore not independent. In view of this, we used a modified Bonferroni correction to adjust for the number of independent tests performed to take into account the fact that the polymorphisms were in LD and the BMD measurements at the spine and hip at baseline and follow-up were strongly correlated. To make this correction, we took an average of the DЈ values for all three polymorphisms (0.92) and subtracted this figure from 1 to get an indication of the number of independent polymorphisms tested [1 ϩ (2 ‫ء‬ 1 Ϫ 0.92)]. According to this calculation, the number of independent polymorphisms tested was 1.16. We analyzed two skeletal sites (femoral neck BMD and lumbar spine BMD), but these were significantly correlated (r ϭ 0.668), and taking this correlation into account, we effectively analyzed 1.66 independent sites [1 ϩ (2 ‫ء‬ 1 Ϫ 0.668)]. Similarly, baseline and follow-up BMD were strongly correlated (r ϭ 0.883), and therefore, the analysis of genotype in relation to baseline and follow-up BMD can be considered as 1.22 independent tests (1 ϩ 2 ‫ء‬ 1 Ϫ 0.883). In total, therefore, we conducted 4.05 independent tests (1.16 ϩ 1.66 ϩ 1.22). Applying a Bonferroni correction to our data using this figure gives an adjusted threshold for significance of P ϭ 0.012, equating to the conventional threshold for significance of P ϭ 0.05. The sample size gave approximately 99% power of detecting a difference of 0.15 BMD Z-score units between genotype groups, assuming a population frequency of 0.20 for the rare allele.
Ethics
Written informed consent was obtained for all the women, and the study was approved by the Grampian Research Ethics Committee.
Results

Characteristics of population
The average Ϯ sd age of the participants at the baseline visit was 48.4 Ϯ 2.3 yr (range 44 -56 yr) and 54.8 Ϯ 2.3 yr at the follow-up visit. The average time between baseline and follow-up visits was 6.3 Ϯ 0.85 yr and did not differ between genotype or haplotype groups (data not shown). At the baseline visit, 44.9% of participants were premenopausal, and 16.9% were current users of HRT. At the follow-up visit, only 3.2% of participants were premenopausal, and the proportion of current HRT users had roughly doubled to 37.5%.
Genotype frequencies for all three polymorphisms were similar to those previously reported in other Caucasian populations (13, 17) . All three polymorphisms were in strong LD, and DЈ values ranged from 0.88 to 0.96 ( Fig. 1) . Genotypes for the Ϫ1997 G/T polymorphism and Sp1 polymorphism were in Hardy-Weinberg equilibrium (P ϭ 0.22 and P ϭ 0.48, respectively), but genotypes for the Ϫ1663indelT polymorphism deviated significantly from Hardy Weinberg equilibrium (P ϭ 0.0003) due to overrepresentation of homozygotes for the Ϫ1663InsT allele and underrepresentation of heterozygotes.
In view of this, we carefully scrutinized sequencing traces from all individuals who were heterozygous for Ϫ1663in-delT and all Ϫ1663delT homozygotes, but no errors were identified, thereby excluding genotyping error as a cause of the Hardy-Weinberg equilibrium deviation. Possible explanations include a greater proportion of failed reactions in Ϫ1663indelT heterozygotes (24) because this polymorphism was technically the most difficult to genotype and had the greatest number of dropouts or because the Ϫ1663indelT polymorphism may actually have been a composite of two polymorphisms within the poly-T tract on different haplotype backgrounds. This has previously been documented as a cause of Hardy-Weinberg equilibrium deviation at other loci (Cox, N., personal communication), but we were unable to investigate this possibility in the present population because the participants were unrelated. Analysis of genotype data by the PHASE software program predicted the presence of all eight possible haplotypes in the study population, but five of these were very rare, and three common haplotypes accounted for 95.4% of alleles at the 5Ј flank of the COLIA1 locus (Fig. 1 ). These were designated haplotype 1 (Ϫ1997G/ Ϫ1663InsT/ϩ1245G), which accounted for 65.3% of alleles; haplotype 2, which accounted for 16.8% of alleles (Ϫ1997G/ Ϫ1663DelT/ϩ1245T); and haplotype 3, which accounted for 13.3% of alleles (Ϫ1997T/1663InsT/ϩ1245G). Alleles of haplotype 1 deviated significantly from the Hardy Weinberg equilibrium (P ϭ 0.002), and there was slight deviation from the Hardy Weinberg equilibrium for alleles of haplotype 2 (P ϭ 0.029). However, alleles of haplotype 3 were in Hardy Weinberg equilibrium (P ϭ 0.16).
Association between individual polymorphisms and BMD
Relevant characteristics of the study population at baseline and follow-up in relation to the individual polymorphisms are shown in Table 1 . The BMD values shown are least square means adjusted for age, BMI, HRT use, and menopausal status at the baseline assessment and age, BMI, HRT use, menopausal status, smoking, and physical activity score at the follow-up assessment.
There was no difference in age, BMI, menopausal status, or HRT use between the genotype groups at the baseline visit, but all three polymorphisms were associated with adjusted BMD at either the lumbar spine and/or femoral neck at baseline. For the Ϫ1997G/T polymorphism, there was a significant association with lumbar spine BMD (P ϭ 0.003), and comparison between genotypes showed that BMD values were significantly higher in homozygotes for the T allele. For the Ϫ1663indelT, there was also a significant association with lumbar spine BMD values (P ϭ 0.006), and for the Sp1 polymorphism, the P value was nominally significant (P ϭ 0.018) but fell below the adjusted threshold for significance of P ϭ 0.012 when multiple testing was taken into account (see Statistical analysis). For both the Ϫ1663indelT and Sp1 polymorphisms, comparison between genotypes showed that BMD values were significantly reduced in rare homozygotes. Nominally significant results were obtained for baseline femoral neck BMD in relation to the Ϫ1663indelT and Sp1 polymorphisms (P ϭ 0.024 and P ϭ 0.048, respectively), but these did not reach the threshold for significance when multiple testing was considered. There was no significant association between Ϫ1997G/T and femoral neck BMD at baseline (P ϭ 0.196). When we performed multiple regression analysis, entering genotypes for all three polymorphisms into the model, assuming a recessive mode of inheritance, we found that homozygosity for the Ϫ1997T allele was an independent predictor of baseline lumbar spine BMD (P ϭ 0.002; 0.32% of the variance) along with BMI (P Ͻ 0.001; 6.09% of the variance), age (P Ͻ 0.001; 0.94% of the variance), menopausal status (P Ͻ 0.001; 3.64% of the variance), and HRT use (P ϭ 0.003; 0.25% of the variance). Taken together, these variables explained 11.24% of the variance in lumbar spine BMD. When we performed a similar analysis for femoral neck BMD, none of the individual genotypes was identified as an independent predictor of BMD (data not shown).
At the follow-up visit, there was a highly significant difference in the proportion of HRT users in relation to the Ϫ1663indelT (P ϭ 0.02) and Sp1 polymorphisms (P ϭ 0.003). For these polymorphisms, the proportion of HRT users in heterozygotes was less than in the other genotype groups, and for the Sp1 polymorphism, there was an excess of HRT users among TT homozygotes. Genotype-specific associations with BMD at the follow-up visit for the Ϫ1997G/T polymorphism were similar to the baseline visit (P ϭ 0.003), except that the association with femoral neck BMD at follow-up was nominally significant (P ϭ 0.039). For the Ϫ1663indelT and Sp1 polymorphisms, the associations with BMD at follow-up were weaker than at baseline, and nominal significance was observed only for the Sp1 polymorphism in relation to lumbar spine BMD (P ϭ 0.037). When we performed multiple regression analysis entering genotypes at all three polymorphisms into the regression model, assuming a recessive mode of inheritance, we found that homozygosity for the Ϫ1997T allele was an independent predictor of follow-up lumbar spine BMD (P ϭ 0.001), accounting for 0.35% of the variance and femoral neck BMD (P ϭ 0.027), accounting for 0.21% of the variance. Other nongenetic predictors of femoral neck and lumbar spine BMD at follow-up were similar to those at the baseline visit (data not shown).
We also analyzed the relationship between individual polymorphisms and unadjusted BMD values at each visit by ANOVA, and this yielded broadly similar results to the adjusted BMD values (data not shown).
Association between COLIA1 5Ј haplotypes and BMD
Relevant characteristics of the study population at baseline and follow-up in relation to the three commonest haplotypes are shown in Table 2 . There was no significant association between any haplotype and age, BMI, menopausal status, or HRT use at the baseline visit, and there was no significant difference in adjusted lumbar spine BMD or femoral neck BMD values at baseline in relation to haplotype 1. There was a significant association between haplotype 2 and baseline BMD at the lumbar spine (P ϭ 0.007) and femoral neck (P ϭ 0.008), with reduced BMD values in homozygote carriers of haplotype 2. There was also a significant association between haplotype 3 and baseline BMD at the lumbar spine (P ϭ 0.007), but the association with baseline femoral neck BMD was not significant (P ϭ 0.224).
Multiple regression analysis showed that haplotypes 2 and 3 were significant predictors of lumbar spine BMD at baseline. Homozygosity for haplotype 2 accounted for 0.26% of the variance in lumbar spine BMD (P ϭ 0.007), and homozygosity for haplotype 3 accounted for 0.19% of the variance (P ϭ 0.007). Other predictors were BMI (P Ͻ 0.001; 6.43% of the variance), menopausal status (P Ͻ 0.001; 3.66% of the variance), age (P Ͻ 0.001; 0.95% of the variance), and HRT use (P ϭ 0.003; 0.27% of the variance). Together these variables predicted 11.76% of the variance in baseline lumbar spine BMD. Homozygosity for haplotype 2 was also a significant predictor of baseline femoral neck BMD (P ϭ 0.004), accounting for 0.25% of the variance. Other predictors were BMI (P Ͻ 0.001; 9.18% of the variance), age (P Ͻ 0.001; 2.57% of the variance), menopausal status (P Ͻ 0.001; 0.64% of the variance), and HRT use (P ϭ 0.048; 0.16% of the variance). Together these variables predicted 12.81% of the variance in baseline femoral neck BMD. At the follow-up visit, there was no difference in age, BMI, smoking, or physical activity score in relation to haplotype (data not shown), but there was a significant difference in the proportion of HRT users in relation to carriers of haplotype 2, with a reduced number of HRT users in heterozygotes and an increased number of HRT users in haplotype 2 homozygotes (P ϭ 0.002). There was no significant difference in adjusted lumbar spine BMD or femoral neck BMD values at follow-up in relation to haplotype 1. There was no significant association between haplotype 2 and follow-up BMD at the lumbar spine, contrasting with the significant association at baseline. Moreover, the association between haplotype 2 and femoral neck BMD at follow-up was weaker than at baseline (P ϭ 0.033). For haplotype 3, the association with lumbar spine BMD at follow-up remained significant (P ϭ 0.004), with a similar effect size as at the baseline visit. Haplotype 3 was associated with femoral neck BMD at follow-up with a nominally significant P value (P ϭ 0.030).
Multiple regression analysis showed that haplotype 3 was a significant predictor of lumbar spine BMD at follow-up. Homozygosity for haplotype 3 accounted for 0.50% of the variance in BMD (P ϭ 0.004). Other predictors were BMI (P Ͻ 0.001; 7.49% of the variance), age (P Ͻ 0.001; 2.563% of the variance), menopausal status (P Ͻ 0.001; 1.55% of the variance), and HRT use (P Ͻ 0.001; 1.1% of the variance). Together these variables predicted 13.2% of the variance in follow-up lumbar spine BMD. For follow-up femoral neck BMD, multiple regression analysis showed that homozygosity for haplotype 2 was a significant predictor of BMD (P ϭ 0.021), accounting for 0.21% of the variance. Haplotype 3 was also a significant predictor of follow-up femoral neck BMD (P ϭ 0.05), accounting for 0.16% of the variance. Other predictors were BMI (P Ͻ 0.001; 8.47% of the variance), age (P Ͻ 0.001; 2.12% of the variance), and menopausal status (P Ͻ 0.023; 0.18% of the variance). Together these variables predicted 10.93% of the variance in follow-up femoral neck BMD. Because haplotypes 2 and 3 had opposing effects on BMD, we stratified participants according to combinations of these two haplotypes. This showed a striking difference in BMD between the extreme genotypes at both baseline and follow-up as illustrated in Fig. 2 . Subjects who were homozygous for haplotype 3 had the highest BMD, and those homozygous for haplotype 2 had the lowest BMD. The difference between haplotypes was greatest for lumbar spine BMD at baseline (P ϭ 0.001) and follow-up (P ϭ 0.008) but was also evident and statistically significant for femoral neck BMD at baseline (P ϭ 0.02) and follow-up (P ϭ 0.012). The difference in BMD between the extreme haplotypes (homozygotes for haplotype 2 vs. homozygotes for haplotype 3) was 0.094 g/cm 2 at the lumbar spine, which is equivalent to about 0.58 BMD Z-score units, and 0.042 g/cm 2 at the femoral neck, which is equivalent to about 0.33 BMD Z-score units. At follow up, the difference in BMD between the extreme genotypes 2/2 and 3/3 was 0.10 g/cm 2 at the lumbar spine, which is equivalent to about 0.81 BMD Z-score, and 0.061 g/cm 2 at femoral neck, which is equivalent to about 0.50 BMD Z-score units.
We also analyzed the relationship between individual haplotypes and unadjusted BMD at each visit by ANOVA, and this yielded broadly similar results to those obtained with the adjusted BMD values (data not shown).
Genotype and haplotype associations with bone loss
There was no significant association between genotype or haplotype and bone loss at either the lumbar spine or femoral neck in the study population. Multiple regression analysis showed that the major predictors of lumbar spine bone loss were HRT use (P Ͻ 0.001; 14.59% of the variance); menopausal status (P Ͻ 0.001; 4.48% of the variance); BMI (P Ͻ 0.001; 3.04% of the variance); and age (P ϭ 0.01; 0.19% of the variance). Together these variables accounted for 22.3% of the variance in bone loss. Similar analysis for femoral neck bone loss showed that the major predictors were HRT use (P Ͻ 0.001; 7.85% of the variance); menopausal status (P Ͻ 0.001; 2.17% of the variance); and BMI (P ϭ 0.01; 0.4% of the variance). Together these variables accounted for 10.4% of the variance in femoral neck bone loss.
Discussion
The COLIA1 gene is a strong functional candidate for the genetic regulation of bone mass and susceptibility to fragility fractures because it encodes the ␣1-chain of type I collagen, the most abundant protein in bone. Most previous studies of COLIA1 alleles in relation to osteoporosis-related phenotypes have focused on the intronic Sp1 binding site polymorphism (2) . The promoter polymorphisms that we studied here were originally identified by Garcia-Giralt et al. (13) on mutation screening of the proximal COLIA1 promoter in 265 postmenopausal Spanish women. In that study, the Ϫ1997G/T polymorphism was the one most strongly associated with BMD, and lumbar spine BMD values were reduced in TT homozygotes, compared with the other genotype groups (13) . Whereas the Ϫ1663InsT/DelT polymorphism was not significantly associated with BMD in Spanish women, regression analysis showed that alleles at the Ϫ1663 and Sp1 site interacted with alleles at the Ϫ1997 site to regulate lumbar spine BMD. The relation between the Ϫ1997G/T polymorphism and BMD has also been investigated in other cohorts. In a study of 308 postmenopausal Caucasian women from the United States, haplotypes defined by the Ϫ1997 and Sp1 polymorphisms were found to be associated with BMD such that higher values were found in carriers of the G allele at both polymorphic sites (17) . Another family-based study in Chinese subjects showed evidence of an association between the Ϫ1997G/T polymorphism and hip BMD using a quantitative transmission disequilibrium testing-based approach (15) , whereas a population-based study of unrelated Chinese women showed no association between Ϫ1997G/T alleles and BMD (25) . A further study of 1100 Japanese postmenopausal women reported a significant association between Ϫ1997G/T alleles and hip BMD with lower BMD values in GG homozygotes (16) .
The present study of promoter and intron 1 polymorphisms at the COLIA1 locus is the largest and most comprehensive to be conducted so far and is the first study to examine the role of all three polymorphisms and haplotypes in relation to BMD. In agreement with the previous study of Spanish women (13), we found that all three polymorphisms were in strong LD and three common haplotypes accounted for more than 95% of alleles at the 5Ј flank of the COLIA1 locus. These were haplotype 1 (Ϫ1997G/Ϫ1666InsT/ ϩ1245G); haplotype 2 (1997G/Ϫ1663delT/ϩ1245T); and haplotype 3 (Ϫ1997T/Ϫ1663InsT/ϩ1245G). Whereas the individual polymorphisms were associated with BMD to an extent, we observed stronger and more consistent associations with BMD in relation to the carriage of the COLIA1 haplotypes and also significant differences in the strength of association by skeletal site and the time point at which participants were studied. For the Ϫ1997G/T polymorphism, homozygotes for the T allele had increased lumbar spine BMD at baseline and follow-up and had increased femoral neck BMD values at follow-up.
These observations are in broad agreement with the findings reported by Yamada et al. (16) , who also reported higher BMD values in relation to the Ϫ1997 T allele in Japanese postmenopausal women. Our findings differ from the results reported in Spanish and U.S. postmenopausal women, however, where the Ϫ1997T allele was associated with reduced BMD (13, 17) . The differences between these studies could be due to the fact that the polymorphisms studied here are in LD with other functional polymorphisms at the COLIA1 locus that regulate BMD and that the patterns of LD differ in these different populations. Another more likely explanation is due to a more accurate estimate of effect in the study by Yamada et al. (16) and this study, which, respectively, were about 3 and 10 times larger than the studies that reported an association between the Ϫ1997T allele and low BMD (13, 17) .
For the Ϫ1663indelT and Sp1 polymorphism, we observed a strong and highly significant association with lumbar spine BMD values at baseline, even after correction for multiple testing, but these associations were weaker at follow-up. The difference that we observed between baseline and follow-up may have been influenced by differential use of HRT in the different genotype groups. This was most marked and sta-tistically significant for the Ϫ1663indelT and Sp1 polymorphisms, for which there was a highly significant difference across genotype groups in terms of HRT use at follow-up, compared with no difference at baseline. This difference in HRT use may be accounted for by the fact that women in this cohort who had BMD values in the lowest quartile at baseline were advised to take HRT to protect against osteoporosis (18) . Because BMD values were significantly lower in homozygotes for the rare allele at the Ϫ1663indelT and Sp1 sites at baseline, this could have accounted for higher rates of HRT uptake at follow-up in these genotype groups.
The association between haplotypes and BMD was stronger and more consistent across skeletal sites than the associations with individual genotypes. Haplotypes 2 and 3 were both strongly associated with lumbar spine BMD at baseline, and haplotype 2 was also strongly associated with femoral neck BMD at baseline. At follow-up, the association between haplotype 3 and lumbar spine BMD was similar to the baseline visit, whereas the association with haplotype 2 was weaker than at baseline and was not statistically significant. These differences were most likely due to differences in uptake of HRT in carriers of haplotype 2, reflected by the significant difference in the proportion of HRT users in this haplotype group at the follow-up visit as compared with baseline. As was the case with the individual polymorphisms, we speculate that this difference may be increased by the use of HRT in homozygote carriers of haplotype 2.
The P values for significance reported here should be interpreted in light of the fact that we studied associations among three polymorphisms and associated haplotypes in relation to BMD at two sites, measured on two occasions. However, taking into account the LD between polymorphisms and the fact that the traits were correlated, many of the associations we observed remained below the adjusted threshold for significance (P ϭ 0.012), using a modified Bonferroni test to correct for the number of independent tests performed.
The haplotype associations that we report here are of interest in relation to a recent study using promoter-reporter assays in which it was shown that promoter constructs containing the Ϫ1997G-DelT allele (corresponding to haplotype 2) had higher rates of transcription than the Ϫ1997T/ Ϫ1663InsT allele (corresponding to haplotype 3) (14) . The effects of the COLIA1 Sp1 polymorphism on transcription were not investigated in the reporter studies mentioned above, but we have recently found that constructs containing the promoter and intron 1 alleles (corresponding to haplotype 2) also drive transcription at higher levels than constructs containing alleles of haplotype 3 (Jin, H., and S. H. Ralston, unpublished data). These observations suggest that there is an association between high levels of COLIA1 transcription and reduced BMD values, consistent with previous work that has suggested that the Sp1 T allele is associated with increased COLIA1 transcription, leading to an imbalance in the ratio of the collagen type I␣1 and collagen type I␣2 chains, resulting in a subtle impairment of bone mineralization (8) . The present observations indicate that the previously reported association between the COLIA1 Sp1 T allele and increased allele-specific transcription (7) may actually be driven by an extended haplotype driven by both the intron 1 and promoter polymorphisms.
In summary, this study demonstrates that haplotypes, defined by the promoter and intron 1 of the COLIA1 gene, regulate BMD in postmenopausal women. One of the most interesting observations to emerge from the study was the much higher uptake of HRT in women who carried genotypes and haplotypes that were associated with low BMD at the baseline assessment. This example of a gene-environment interaction illustrates the challenges faced by investigators who seek to detect genetic variants that regulate BMD in populations such as this, in which systematic BMD screening has been followed by a specific therapeutic intervention. Whereas the mechanism by which COLIA1 variants regulate BMD remains to be fully elucidated, current evidence is consistent with an effect of these different haplotypes on COLIA1 transcription.
